Company Overview

Orgenesis Inc. (NASDAQ: ORGS) is a biotechnology and cell therapy company focused on developing and commercializing decentralized manufacturing platforms for advanced therapies, particularly cell and gene therapies. The company operates within the regenerative medicine, bioprocessing, and contract development and manufacturing organization (CDMO) industries. Orgenesis has positioned itself around enabling point-of-care and localized production models intended to reduce manufacturing complexity, lower costs, and improve accessibility for personalized therapies.

The company’s primary business activities include cell therapy processing technologies, therapeutic development support, and decentralized manufacturing infrastructure through its POCare Platform and related services. Orgenesis has historically emphasized autologous cell therapies and collaborative manufacturing networks serving biotechnology firms, hospitals, and research institutions. Founded in 2008, the company initially focused on regenerative medicine technologies and later expanded into cell and gene therapy manufacturing services, evolving toward a platform-oriented business model centered on distributed production capabilities and process standardization.

Business Operations

Orgenesis conducts operations through multiple business units focused on advanced therapy manufacturing, processing technologies, and development services. Its principal operating activities include the provision of decentralized manufacturing solutions, process development, quality systems, and automation tools supporting cell and gene therapy production. The company has emphasized its POCare Platform, which integrates manufacturing expertise, automation technologies, and local production frameworks intended to support personalized medicine applications. Revenue has historically been generated through service agreements, collaborative development arrangements, licensing activities, and manufacturing-related support.

The company maintains both domestic and international operations, with activities spanning North America, Europe, the Middle East, and parts of Asia. Orgenesis has established relationships with hospitals, research centers, and biotechnology organizations to support localized manufacturing deployment. The company has also operated through subsidiaries and affiliated entities involved in cell processing, bioprocess development, and therapeutic innovation. Public filings and corporate disclosures indicate that Orgenesis has pursued joint ventures and strategic collaborations to expand manufacturing capacity and regional market access, though some partnership structures and financial impacts are not consistently detailed across public sources.

Strategic Position & Investments

Orgenesis has strategically focused on decentralized and point-of-care manufacturing as an alternative to centralized large-scale production models commonly used in the cell and gene therapy industry. The company’s growth initiatives have centered on expanding its global manufacturing network, increasing automation capabilities, and supporting scalable therapeutic production closer to patients and treatment sites. This strategy aligns with broader industry trends emphasizing reduced logistics complexity and faster turnaround times for personalized therapies.

The company has invested in manufacturing technologies, processing systems, and collaborative infrastructure through acquisitions, licensing arrangements, and partnerships. Orgenesis has publicly highlighted involvement in emerging sectors including regenerative medicine, cell processing automation, and advanced therapeutic manufacturing systems. Subsidiaries and affiliated operations have included entities supporting bioprocess engineering, clinical manufacturing, and therapeutic development initiatives. While the company has announced multiple strategic collaborations and investments over time, the long-term commercial contribution of several initiatives remains difficult to independently verify through public financial disclosures alone, and certain operational details are data inconclusive based on available public sources.

Geographic Footprint

Orgenesis is headquartered in the United States, with corporate activities historically centered in Germantown, Maryland. The company has developed an international operational footprint through subsidiaries, partnerships, and collaborative manufacturing relationships across North America, Europe, the Middle East, and parts of Asia. Public disclosures have referenced operational and strategic activities in countries including Belgium, Israel, and other regional biotechnology markets.

The company’s international strategy has focused on establishing localized manufacturing ecosystems capable of supporting regional healthcare providers and biotechnology organizations. Orgenesis has pursued cross-border collaborations intended to facilitate technology transfer, manufacturing standardization, and regional commercialization opportunities within the advanced therapy sector. Its distributed operational model differentiates it from traditional centralized manufacturing organizations by emphasizing geographically dispersed production capabilities.

Leadership & Governance

Orgenesis leadership has emphasized the development of scalable decentralized manufacturing systems for advanced therapies, with strategic priorities focused on accessibility, process standardization, and global manufacturing integration. Governance and executive oversight are conducted through the company’s board of directors and senior management team, with leadership changes and organizational restructuring periodically disclosed through public filings and investor communications.

Key executives and leadership figures associated with Orgenesis include:

• Vered Caplan – Executive Chairperson
• Moran Amit – Chief Executive Officer
• Ran Nussbaum – Director
• Jonathan Sackner-Bernstein – Former Chief Medical Officer and strategic advisor roles referenced in public disclosures
• David Chaim – Former executive leadership roles associated with operational development initiatives

Executive composition and leadership roles have evolved over time, and certain historical management positions differ across reporting periods. Publicly available information from company filings and market disclosures generally supports the company’s governance structure, though some executive role timelines are not fully consistent across all sources.